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Introduction
Spectacular progress has been made in the last decades in the global fight
against deficiencies of iodine and vitamin A [1]. As a result, the number of
people suffering from iodine deficiency has been reduced from about 1.5
billion in 1990 to about 0.5 billion now, almost entirely due to the introduction
in many countries of what has been termed ‘universal salt iodization’. In
addition, approximately one million child deaths may have been prevented
between 1998 and 2000 by vitamin A supplementation [2]. The political and
financial commitment that has allowed these achievements has been
generated to a large extent by scientific studies that have shown the extent
of human suffering caused by these deficiencies, and that have determined
the potential health gains of interventions. Progress in eliminating
deficiencies of other micronutrients, notably iron, has been much slower.
About two billion people, or about one third of the human population,
continue to suffer from iron deficiency.
Iron supplementation programs have been advocated for infants and
preschool children, largely because of concerns of possible adverse effects of
iron deficiency on mental and motor development. Similar concerns were
instrumental in establishing salt iodization programs. The questions that will
be addressed in this chapter concern the extent to which a shortage of iodine
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and iron during fetal and infant development impairs mental development,
and the extent to which this impairment can be redressed by increasing the
intake of these micronutrients. First, the stages of brain development in the
fetus and infant will be addressed, followed by an assessment of the timing of
vulnerable periods when the brain of the fetus and infant is at high risk of
exposure to an inadequate supply of iodine or iron. Where possible, the
mechanisms involved will be discussed. Then, observational and intervention
studies will be reviewed that have examined the effect of deficiencies of
iodine or iron on mental development.
Approximately half of the world’s population may be at risk of low zinc
intake [3]. Given this high prevalence, inconclusive but mounting evidence
that zinc deficiency during pregnancy may possibly impair the infant’s
neurobehavioral development and immune function should also raise great
concern [4–10]. However, because of space limitations, such effects and those
of other micronutrients [11] will not be reviewed in the present report.
Development of the Nervous System of the Embryo and Fetus
Gestational age, the time scale generally used to gauge prenatal growth, is
derived from the date of the onset of a women’s last menstrual period before
conception. This method makes the embryo or fetus about 15 days older than
when age is determined from the date of conception. The first 2 weeks
following conception, known as the ‘germinal period’, involves cell division
and migration of the newly fertilized egg to where it becomes implanted in the
uterine wall. At this time, the blastocyst, as it is known, consists of a spherical
outer cellular layer that eventually becomes various membranes providing
nutritive support for the embryo, and a second inner group of cells organized
into a mass that will develop into the embryo.
The next stage of development from 2 to 8 weeks after conception, the
‘embryonic period’, is marked by rapid differentiation of cells to form most of
the organs and systems within the body. Such differentiation is achieved by
migration and production of specialized cells with distinct functions. Initially,
3 layers are formed: an inner layer or endoderm that gives rise to the lining
of many internal organs; the middle layer or mesoderm that gives rise to
skeleton, muscle, connective tissue and the urogenital, lymph and
cardiovascular systems, and the outer layer or ectoderm that gives rise to
skin, hair, nails, and, important from the point of view of this chapter, the
nervous system.
At the beginning of the embryonic period, 15 days after conception, a small
group of cells at one end of the ectoderm starts to grow rapidly. Such growth
creates a reference point for the cephalic (head) and caudal (tail) regions of
the embryo and helps to distinguish the left from the right side. The signaling
for the creation of this reference point is provided by retinoic acid produced
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in the mother from retinol. If the supply of retinoic acid is not optimal, the
polarization process will not be successful and will lead to congenital
abnormalities or fetal death [12]. The growth also results in the development
of the neural tube. At about the 4th week, rapid changes in the neural tube
begin. Initially, the tube closes in the cephalic region and later in the caudal
region. Failure to close in the cephalic region results in anencephaly in which
the cerebral hemispheres and cortex fail to develop, resulting in a newborn
that will survive only a short time. Failure of the neural tube to close in the
caudal region results in spina bifida in which spinal nerves grow outside the
protective vertebrae. Folic acid deficiency and perhaps deficiencies of other
B vitamins increases the risk of the neural tube failing to close [13].
From 4 to 8 weeks, there is continued rapid development of the head and
brain with an enormous increase in the nerve cells: once the neural tube is
closed, such neurons also migrate extensively and make contact with one
another. Thus, from 4 weeks onwards, maternal deficiency of iodine, and
perhaps even of iron, can have profound effects on fetal development. Even
by the 5th week, the nervous system starts to function as can be witnessed
by faint irregular brain wave activity. From 4 to 11 weeks after conception,
which is beyond the embryo period, the corpus callosum develops. It connects
the two cerebral hemispheres together and provides a pathway from one side
to the other. The absence or malfunction of this structure results in seizures
and mild to moderate mental retardation, as well as impaired visual and motor
coordination.
The next stage of development from 9 weeks until parturition, the ‘fetal
period’, is marked by growth in size and the genesis of processes that assist
organs and systems to function. By the end of the first trimester, behavior
such as opening and closing lips, skin movements on the forehead and head
turning, become more coordinated while by the end of the second trimester,
brain wave patterns are nearly up to the level of that of the newborn. The
growth spurt of the brain starts in the second trimester. The process of
neuron proliferation that began 4 weeks after conception continues for a
further 16 weeks while neuron migration continues to the end of the second
trimester. In the third trimester, the cerebral hemispheres, the regions of the
brain most heavily involved in complex mental processing, grow rapidly,
folding and developing fissures to give them a wrinkled appearance. In
addition to the neurons, there are an equal number of glial cells, which
normally divide up to about 2 years of age but retain the potential to divide
throughout life. There are 2 groups of glial cells: the macroglia, which include
the astrocytes and the oligodendrocytes, and the smaller microglia, which act
as macrophages in the brain. The astrocytes form part of the blood-brain
barrier and are located close to the blood vessels while the oligodendrocytes
synthesize and maintain the myelin sheath in the white matter of the brain
and serve as neuronal satellite cells in the gray matter of the brain. In fact,
myelin is responsible for the white color of white matter. Myelination begins
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at about 26 weeks after fertilization but continues postpartum, peaking when
the child is 14–18 months of age. By the age of 1 year, the brain has reached
approximately 70% of the adult’s brain weight, and by the age of 2 years this
has increased to 80% [14], whilst brain maturation probably continues
through adolescence and beyond.
With respect to iron, much of our limited knowledge on its importance in
brain development comes from studies on rodents and other animals. It is
important to take into account, however, that rodents and humans differ in
the timing of birth relative to the degree of maturation of the brain at birth
[15]. Growth of the human brain is slower than that of rats, and brain
development in the rat at postnatal days 12–14 is perhaps comparable to that
in human babies near term. Early programming effects may be expected to
occur foremost during the perinatal and early postnatal period in rats, and
over a much longer period in humans including both gestation and the first
years of life.
Timing of Deficiencies of Iodine and Iron in Relation to Brain
Development and Functioning
Profound changes occur during normal pregnancy and lactation both in
maternal micronutrient status and the supply of micronutrients to the
developing brain of the child. An assessment of these changes is helpful to
identify periods during which the fetus and young infant are most likely to
become exposed to a limited supply of micronutrients, and thus to single out
critical phases during which micronutrient deficiency can result in impaired
brain development or neurological functioning.
The fetus is dependent on the placenta for its supply of nutrients. Such
nutrients traverse the placenta bound to carrier proteins, or incorporated 
into compounds. Postpartum, nutrients are derived from the diet with 
the effective supply depending on the amount of food or pharmanutrient
(pharmaceutical preparation) consumed, the nutrient content of such food or
pharmanutrient, and the bioavailability or bioefficacy of precursors of such
nutrients [16]. For the infant, nutrient status depends on what comes from
the mother preterm, and what is ingested postpartum from breast milk,
supplementary foods or pharmanutrients. The flow of iodine and iron of
interest to the fetus and infant is discussed below.
Iodine
Iodine carries out its function in the body as a part of the hormones,
thyroxine (T4) and triiodothyronine (T3) produced by the thyroid gland (fig. 1).
However, initially the fetus cannot utilize iodine directly: it is dependent on
the mother for T4 but after about 18–22 weeks the fetus gradually becomes
more independent of the mother as it starts to synthesize its T4 from iodine
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supplied via the placenta [17]. This is because the thyroid and pituitary
responsible for the production of T4 and thyroid-stimulating hormone
respectively develop by 12 weeks, while the hypothalamus, responsible for
the production of thyrotropin-releasing hormone, develops from the 10th to
the 30th week. However, newborns incapable of synthesizing their own
thyroid hormones due to genetic defects have cord serum T4 values of
20–50% of those of normal newborns indicating that transplacental transfer
of maternal T4 continues until birth [18]. When the iodine supply to the
thyroid gland is limited, the gland produces relatively more T3 than T4. When
T4 levels are low, target tissues also convert T4 to T3. However, the brain can
only take up T4 but not T3, so brain function is affected when T4 levels are low
even though there may be sufficient T4 and T3 to carry out the function of
thyroid hormones in other organs/tissues. This is particularly important for
the fetus in the first half of pregnancy. If maternal T4 levels are low, the fetal
brain will be exposed to low T4 levels, and this will result in brain damage.
Selenium has been found to be a component of various deiodinases thus
explaining why selenium deficiency can contribute to the development of
iodine deficiency disorders in areas where both iodine and selenium are
deficient [see chapter by Delange]. Two deiodinases are of particular interest:
type I or ID-I which is a 5-deiodinase producing the normal form of T3
(lacking an iodine atom in the outer ring) and type III or ID-III which is a 
5-deiodinase producing reverse T3 (lacking an iodine atom in the inner ring).
From 20 weeks of gestation almost to the end of pregnancy, ID-III is active
resulting in low levels of normal T3 while just prior to birth, there is a change
to ID-I that produces the normal form of T3.
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Fig. 1. Role of the thyroid gland,
pituitary gland and hypothalamus 
in the synthesis and release of 
thyroid hormones. TRH  Thyrotropin-
releasing hormone; TSH  thyroid-
stimulating hormone or thyrotropin;
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Thus it appears that in iodine-deficient mothers the fetal brain has the
highest risk of becoming exposed to iodine deficiency during the first half of
pregnancy, and that this risk gradually declines until delivery and beyond. In
addition, maternal selenium deficiency may increase the risk of brain iodine
deficiency in the second half of the pregnancy. Because the brain may
undergo ‘critical periods’ whereby iodine deficiency has differential effects in
the course of its development, maternal deficiencies of iodine and selenium
may produce different long-term effects despite the fact that they may both
induce iodine deficiency in the fetal brain. Given differences in the
geographical distributions of these deficiencies, this might explain why the
syndromes related to iodine deficiency are different in various parts of 
the world.
Iron
Iron plays a critical role in brain development, including its postnatal
stages. Youdim et al. [19], Youdim [20], Rouault [21] and Beard [22–24]
reviewed the biological mechanisms whereby iron deficiency could possibly
affect brain structure and functioning. The accumulation and distribution of
iron in various regions of the brain depend on the stage of its development.
This might indicate that brain regions vary in their vulnerability to iron
deprivation, and suggests that the effect of iron deficiency on brain iron
content could depend on the timing of the exposure. Animal studies indicate
that low dietary intake of iron in the neonatal or preweaning period (before
postnatal days 14–21) may reduce whole-brain iron content that is not
reversible by dietary repletion and produce irreversible effects. In rats, such
effects occur before completion of brain organization and myelination and
establishment of the dopaminergic tracts. By contrast, dietary depletion in
the postweaning period can also reduce brain iron content but this might be
reversible upon dietary repletion. This illustrates that the timing of exposure
to iron deficiency must be carefully considered when examining possible
effects of iron deficiency on mental performance.
Iron is not only required for brain growth and differentiation of neuronal
cells, but also for protein synth sis, hormone production and other aspects of
cellular energy metabolism and functioning. When sufficiently severe to
reduce hemoglobin concentrations or cause anemia, iron deficiency might
adversely affect oxygen delivery, thereby leading to reduced functioning of
the central nervous system. Such deleterious effects of iron deficiency might
be partially or completely reversed by iron repletion.
Effects of iron deficiency might also be determined by other mechanisms.
For example, it has been hypothesized that anemic children experience
delayed acquisition of new skills, because they explore and interact less with
their environment than nonanemic children, and they induce less stimulating
behavior in their caretakers. Additionally, several studies have indicated that
anemic children tend to be more fearful, withdrawn and tense, have a reduced
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ability to focus their attention [25, 26], and are therefore less exposed to
environmental stimuli that may promote mental and motor development.
Iron requirements during pregnancy can be calculated on the basis of basal
iron losses in non-pregnant women, iron deposition in the fetus and related
tissues, and iron utilized in the expansion of hemoglobin mass [27–29]. In
supplemented US women assumed to be iron-replete, the median require-
ments of absorbed iron over the entire pregnancy period are estimated at
250 mg (basal losses)  320 mg (fetal and placental deposits)  500 mg
(increase in hemoglobin mass), or 1,070 mg [28]. Due to their smaller body
size, the iron needs in iron-replete women in developing countries are
probably somewhat less. However, the utilization of iron is uneven during
pregnancy. Because of the absence of menstrual iron losses and the negligible
needs of the fetus, iron requirements in the first trimester are very low and
are probably even less than in menstruating women [30]. In addition, there
are indications that erythropoiesis is less than in menstruating women, which
would also suggest that iron needs are reduced [31]. The total requirements
as well as the requirements for deposition in the fetus and related tissues
increase markedly during the second trimester and reach their maximum
during the third trimester. These demands may be increased by helminth
infections. There is a broad consensus that iron demands during the second
half of pregnancy may not be met by dietary sources in most developing
countries, and that sufficient stores must be present at conception to avert
subsequent development or exacerbation of iron deficiency at later stages of
pregnancy.
These iron balance calculations implicitly assume that unconstrained
erythropoiesis and maximal hemoglobin concentrations are required as an
indication that all functional needs for iron have been met. This supposition
has recently been questioned by Beaton [32] who argued that documented
adverse health effects in mothers or infants only appear to occur at
hemoglobin concentrations far below (90 g/l) the cutoff values of 110 g/l
as indicated by the World Health Organization or, more recently, by normal
values defined the US Centers for Disease Control and Prevention [33]. Iron
supplementation has a limit d effect on maternal hemoglobin concentrations
when the latter have reached values of 110 g/l, suggesting that these values
are close to their potential and iron need is marginal [32]. The question
therefore arises to what degree mild maternal iron deficiency impairs the
placental transfer of iron to the fetus. This transfer, which is mediated and
largely regulated by the expression of placental transferrin receptors, is
generally thought to be relatively independent of maternal iron status [34–36],
so that mild maternal anemia has no or little effect on iron stores in the
newborn infant. Because of the high affinity of fetal hemoglobin for oxygen,
the fetus ‘wins’ over the mother in the struggle for oxygen at the placental
interface [37]. As a consequence of this high affinity, delivery of oxygen from
fetal hemoglobin to tissues is lowered, and the fetus needs high hemoglobin
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concentrations to meet tissue oxygen demands. After delivery, oxygen is
more readily available from the lungs, and the hemoglobin circulating at birth
is in excess of what is needed. Erythropoiesis stops within days after delivery
[38, 39], and elimination of red cells that have reached the end of their life
span results in a dramatic drop in hemoglobin concentration in the first 
2 months of life. The iron thus released is used to build up the iron stores of
the infant, which are considered to be sufficient for the first 4–6 months of life.
The point of the rather long discussion in the two preceding paragraphs is
to emphasize that iron deficiency has been generally considered uncommon
during pregnancy and in children with normal birth weights (2,500 g) until
beyond 4–6 months of life (fig. 2). Exclusively breast-fed term infants are
thought to rarely show any signs of iron deficiency at 6 months of age [38, 39].
Iron requirements in infants 6 months of age born full-term are believed to
be negligible, and iron absorption low [35]. Interventions to increase iron
intake in this population are therefore considered not efficacious or cost-
effective. Current guidelines from the International Nutritional Anemia
Consultative Group, the World Health Organization and UN Children’s Fund
exclude children 6 months with birth weights 2,500 g from iron
supplementation programs recommended in populations at risk of iron
deficiency [42, 43].
This conventional wisdom is being challenged by mounting evidence that
infants in developing countries born at full-term with normal birth weight
(2,500 g) often have anemia when aged between 3 and 6 months, and that
hemoglobin concentrations in this age range are below their potential values
[42–45]. Such findings are consistent with other reports [for review see, 42]
that infants with adequate birth weight but born to anemic mothers have low
iron stores and are more likely to develop anemia than their counterparts
born to nonanemic mothers. This issue is of great importance because
conventional wisdom would imply that in children in developing countries
with normal birth weights (perhaps 80% of all live births), the period during
which the brain undergoes its greatest growth spurt is believed not to
coincide with exposure to iron deficiency.
McElroy et al. [45, 46] followed a large cohort of Kenyan singleton children
born full-term and with normal birth weight in an area with very high malaria
transmission. In each child, blood samples were collected monthly from birth
onwards, and at any time when the axillary temperature was 37.5°C.
Malarial parasitemia was assessed by microscopic examination of blood slides,
and a history was determined of parasitemia exposure in the 90 days
preceding each hemoglobin concentration. Thus, hemoglobin concentrations
in infants aged between 3 and 6 months and without documented parasitemia
in the preceding 90 days were approximately 20 g/l below values for a similarly
aged reference population of healthy, well-nourished Caucasian US, Jamaican
and Nigerian children (fig. 3). By contrast, the hemoglobin concentrations 
of these 2 groups were similar at birth and during the first 2 months of life. 
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Fig. 2. Brain growth in relation to a risk of exposure to iron deficiency, and to current
guidelines for iron supplementation. The growth spurt of the human brain starts in the
second trimester of pregnancy and continues into the 2nd year after birth, although
maturation may continue through adolescence and beyond. In pregnancy, the greatest
risk of exposure to iron deficiency in the mother occurs in the second half of the
gestational period, when the maximal amount of iron potentially absorbed by the
intestine is insufficient to meet the demand posed by the expanding erythroid mass.
It is commonly believed that, in pregnancies leading to term deliveries (37 weeks)
with normal birth weight (2,500 g), iron deficits leading to mild anemia in the third
trimester do not substantially affect placental iron transfer to the fetus. Thus it is
believed that iron deficiency does not occur in these infants during pregnancy, that
iron stores in these infants at delivery are believed to be sufficient for the first 4–6
months of life, and that exclusively breast-fed term infants rarely show any signs of
iron deficiency at 6 months of age. Ideally, maternal iron supplementation should start
at conception (or perhaps even before), but this is not practical in most conditions.
Current guidelines therefore recommend maternal iron supplementation during 
6 months of pregnancy and, where 40% of pregnant women have hemoglobin
concentrations 110 g/l, supplementation should be continued to 3 months
postpartum to acquire sufficient iron stores (A). The latter may not be beneficial to
the newborn, because breast milk is thought to be little responsive to the iron status
of the mother. In areas where iron-fortified foods are not widely and regularly
consumed by young children, iron supplementation has been recommended in
children with birth weights 2,500 g when aged 6–12 months, and until 24 months of
age where the prevalence of anemia in children aged 6–24 months exceeds 40% (B).
Infants who were born premature, with low birth weight, or whose mother was
severely anemic during pregnancy, have fewer iron stores at birth and develop iron
deficiency at an earlier age; they therefore may need iron supplementation starting at
or in some cases even before 2 months of age. See text for further explanation.
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It could not be excluded, however, that decreased hemoglobin concentrations
observed between 3 and 6 months of age could still reflect malaria-associated
anemia, either due to effects from maternal malaria during pregnancy, or to
subpatent parasitemia after birth. Nevertheless, if maternal infection would
have been a major cause one would not expect these children to be born with
such normal hemoglobin concentrations (Dr. Feiko ter Kuile, Centers for
Disease, Control and Prevention, Atlanta, Ga., USA, personal communication).
It can also not be excluded that other factors such as vitamin A deficiency may
also have contributed to the low hemoglobin concentrations observed [46].
In a cross-sectional study in Indonesian infants, De Pee et al. [44] observed
that 37% of those aged 3–6 months had anemia defined by a hemoglobin
concentration of 100 g/l. In those with birth weights of 2,500 g and whose
mothers were not anemic at the time of blood collection in their infants, this
prevalence was 32%, whilst maternal anemia (hemoglobin concentration
120 g/l) at the time of the survey was associated with an increase in the
prevalence of anemia in their infants to 45%. Compared with infants in
Central and West Java, the prevalence of anemia was highest in their
counterparts in East Java, whereas the proportion of mothers who had
received vitamin A supplements postpartum was lowest in this area. Although
confounding by other factors cannot be excluded, and causality cannot be
determined by cross-sectional observations, this observational evidence is
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Fig. 3. Comparison of changes in hemoglobin concentrations with age between
Kenyan children and reference values obtained from populations of healthy Caucasian
US, Jamaican and Nigerian children [46]. Kenyan children lived in an area highly
endemic for malaria and all were singleton, full-term births with normal birth weight
(2,500 g). Parasitemia values were calculated as geometric means of values obtained
from blood samples collected during monthly surveys and at any time when febrile
episodes (axillary temperature 37.5°C) occurred in the 90 days preceding
measurement of hemoglobin concentrations. With permission from the American
Journal of Tropical Medicine and Hygiene.
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compatible with the view that vitamin A deficiency did not substantially
contribute to the anemia observed. Thus it is plausible that the hemoglobin
concentration in these infants might respond to an improvement in maternal
iron status during lactation or pregnancy.
In a trial in Niger, women were recruited at approximately 6 months of
gestation and with hemoglobin concentrations between 80 and 120 g/l and
randomly assigned to iron supplements or placebo for the remainder of 
their pregnancy [47]. Compared to those receiving placebo, iron-supplemented
women had marginally higher hemoglobin concentrations when measured just
before delivery, and a substantially lower prevalence of iron deficiency as defined
by a serum ferritin concentration of 12g/l. Maternal iron supplementation
resulted in somewhat but statistically higher serum ferritin concentrations 
in infants aged 3 months (arithmetic mean 99 versus 80g/l). When aged 
6 months, a high proportion of infants whose mothers had received placebo had
low serum ferritin concentrations indicating no or marginal iron stores, whereas
those whose mothers had received iron had higher values (arithmetic mean 26
versus 15g/l). Hence, maternal iron supplementation resulted in increased iron
stores in their infants aged 3–6 months. The low iron stores at 6 months of age
seem unexpected, but it cannot be excluded that these are explained at least in
part by the occurrence of low birth weights and the early introduction of weaning
foods in the population studied. It is not possible to attribute the low serum
ferritin concentrations observed to concurrent infections, because these would
have resulted in increased values. It also seems unlikely that premature delivery
or low birth weight could have contributed substantially to such low values.
In a cohort study in Jordan [49], pregnant women with hemoglobin
concentrations either 110 g/l (mean  SD 9.9  0.7 g/l) or 110 g/l at 37
weeks of gestation were recruited and followed, together with their resulting
offspring. Only 4% of children had birth weights 2,500 g. Anemic mothers
had lower plasma ferritin concentrations that persisted at 6 months
postpartum. When aged 6 months, infants in these 2 groups had a prevalence
of iron deficiency anemia (hemoglobin concentration 110 g/l, and plasma
ferritin concentration 12g/l or plasma zinc protoporphyrin concentration
35g/l) of 41 and 29%, r spectively, with morphological signs of red cells
compatible with iron deficiency.
In a study in Honduras, Dewey et al. [50] found that 66 and 32% of exclusively
breast-fed, full-term infants born to primiparous women had hemoglobin con-
centrations of 110 or 103 g/l, respectively, whilst 17 and 22% were iron-
deficient (serum concentrations of ferritin 12g/l and C-reactive protein
	10 mg/l). Similarly high prevalences of children with serum ferritin concentra-
tions 12g/l were observed when the analysis was restricted to infants with
birth weights between 2,500 and 3,000 g; in this category, the prevalence of
infants with hemoglobin concentrations 103 g/l was close to 50%.
In the studies reviewed above, helminth infections are unlikely to have
contributed substantially to iron demands in infants 6 months. In the
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Kenyan study, such infections were not assessed, but a subsequent survey in
the same study area found that only 2.3% of infants had hookworm infection
[46]. Even on the island of Zanzibar, off the Tanzanian coast, where Ascaris,
Trichuris and hookworm are highly endemic as shown by high prevalence of
these infections in preschool children, the prevalence of each of these
infections was only 17% in children aged 4–11 months [51]. Additionally,
hookworm infections in children 30 months had low densities, and there
was no evidence that such infections were associated with decreased
hemoglobin concentrations (analysis adjusted for reported fever in the week
before examination, sex, and malaria parasite density).
The strength of the Kenyan study is mainly in its size, and the method of
analysis which probably eliminated malaria as an important contributor to the
anemia observed. An important finding from the study from Indonesia was
that anemia may be common in exclusively breast-fed infants from the age of
3 months onwards. This corroborates the findings from the Kenyan study.
Unfortunately, serum ferritin concentrations could not be measured in either
study, so that it could not be ascertained whether the anemia observed was
indeed associated with iron deficiency. The study from Niger confirmed that
the low iron status observed in infants aged 6 months is due at least in part
to poor iron status in the 3rd month of pregnancy and is reversible by
supplementation. Unfortunately, this report provided no data on breast-
feeding practices.
Despite these limitations, the evidence from these studies indicates that
iron deficiency might be common, and hemoglobin concentrations reduced,
in breast-fed infants aged between 3 and 6 months, born at term and with
normal birth weight. If true, this would imply that iron stores at birth in these
children are less than expected and that there is a need to reassess the
assumption that placental iron transfer to the fetus is relatively independent
of maternal iron status in pregnant women who are mildly to moderately
anemic. This would also mean that these children might have been exposed
to iron deficiency during the fetal stage, with adverse effects on brain
development or functioning as a possible consequence. This and recent
findings from rodent studies [20] that iron deficiency during the course of
early brain development, both prenatally and postnatally, may irreversibly
impair learning ability should raise concern.
Evidence of Effects on Mental and Motor Development
Methodological Issues
Many observational studies have shown an association between a
deficiency of single nutrients, in particular iodine or iron, and poor mental and
psychomotor development. However, children with one deficiency often 
also have deficiencies of other nutrients, or may be exposed to many other
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environmental factors such as infections or factors associated with poverty,
which might also explain the associations observed. Randomized placebo-
controlled trials are unique in their ability to show causal relationships
between deficiency and child development. It is important to distinguish
between therapeutic and preventive trials. In the former, children already
exposed to deficiency are supplemented, and such trials can be efficacious
only if effects were irreversible. By contrast, preventive trials are conceived
to assess the efficacy of supplementation in children who have remained
sufficient in the micronutrient under investigation until the start of the
intervention.
With respect to iron, therapeutic effects on mental or motor development
have been assessed within days or several weeks in several trials. This seems
primarily based on expectations of a rapid response similar to quick
recoveries in hematological indicators or behavior that may be observed
following supplementation in individuals with demonstrated iron deficiency.
However, the full hematological effects of iron supplementation may take
longer to develop [52]. Hence, if the effects on mental or motor function were
mediated by oxygen transport, then it would make more sense to assess
outcomes only after several weeks or even months, as has been done in other
trials [53].
Most trials with iron have been conducted in children beyond early infancy
(6 months of age), presumably because younger children have been
considered at no or little risk of deficiency. Evidence from trials in older
children are nevertheless considered in the present report because they may
give indications about possible effects in younger children if it were assumed
that the effects are reversible.
No instruments are available to ascertain levels of cognition in infants, or to
reliably predict intelligence or mental competence at older ages. Most studies
have used either the Bayley scales of mental and motor development for infants
and toddlers, Wechsler test series for preschool children (WPPSI),
schoolchildren (WISC) or adults (WAIS), or the Raven Progressive Matrices
test. The Bayley scales actually intend to measure the behavioral repertoire of
the infant [54], which might give clues about the current state of mental
development. The Wechsler test consists of 12 subtests, each measuring a
different aspect of the intelligence domain. When combined into a composite
score, the results give an indication of the overall intellectual capacity (IQ). The
Raven test is probably the most widely used culture-reduced test, that is a test
designed to produce results that are minimally influenced by the cultural
context in which it is used. Its results are highly correlated with several other
intelligence tests, and give a good indication of overall intelligence. In a normal
population, 68% of individuals are expected to have scores within 15 points
deviating from the mean value of 100 points.
Results from several studies can be weighed according to their sample size
and quantitatively summarized in a meta-analysis (‘analysis of analyses’)
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[55, 56]. The results are not always interpreted correctly, and we therefore
briefly review the possible goals of such analyses. A meta-analysis may produce
an overall summary estimate of the effect of an intervention and additionally an
estimate of differences between studies. In practice, most individual trials use
small sample sizes and therefore produce imprecise effect estimates [57], which
may leave the impression that the findings from different studies show
conflicting or at least mixed results. A meta-analysis unites data from numerous
studies that on their own would have given inconclusive results [58]. Bias may
still occur, of course, if individual studies have a common systematic error.
Differences in results of the individual studies are also determined.
Systematic variations in effect estimates may be expected to occur, for
example because of differences in the characteristics of the populations
studied (e.g. differences in age or the severity of the deficiency) or the length
of the follow-up period. A test for heterogeneity may be helpful to decide
whether the differences observed between studies could be due to chance. 
If not, a search may be instigated for factors that modify the response. This
may assist in identifying populations at high risk, and in which subsequent
efficacy studies may be conducted. Effect sizes measured on continuous,
normally distributed outcome variables may be reported as the d statistic,
which indicates the standardized mean difference between 2 groups. 
A difference in intelligence test scores of 15 points corresponds to a d value
of 1 standard deviation.
Meta-Analysis of Correlations with Overall Cognitive Performance
We conducted a MEDLINE search to identify observational and
intervention studies that examined associations of increased intake of iodine
or iron with overall cognitive performance with outcomes assessed in children
aged 12 months (in 1 case, 6 months) to 15 years (in 2 cases, 20 and 45 years).
This analysis was restricted to those studies that assessed effects on either 
a series of tests such as the Wechsler Intelligence Scale for Children (WISC),
or on a specific test such as the Raven. Thus studies examining effects 
on psychomotor development, or focused on specific aspects of child
development (e.g. play, affect, or language development) were not included.
The vast majority of the studies thus identified were not amenable to
formal statistical analysis. Among a range of other limitations, many studies
compared several communities rather than individuals, so that observations
were dependent and additionally comprised only a few units of analysis. Most
intervention studies had not used placebos or other controls. In an attempt to
improve the comparability of the intervention studies, we decided to restrict
our analysis to groups receiving the intervention, and to analyze test results
before and after interventions as if they were independent. Similarly, in the
observational studies we assumed that observations were independent.
Despite or perhaps because of these drastic measures, our analysis remained
severely handicapped. Studies were weighted by size, and variability between
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studies was taken into account by using a random-effects model. Thus the
point estimates and corresponding confidence intervals presented below may
be severely biased, the results (fig. 4–7) should therefore be interpreted with
utmost caution. The individual studies seem to indicate consistently that both
iodine or iron are correlated with better cognitive performance.
Iodine
From studies in New Guinea and elsewhere, it has been shown that very
low levels of maternal iodin  intake during pregnancy induce cretinism and
that cretinism in children can be prevented by supplementation of mothers.
Pharoah et al. [94] observed children in New Guinea who were born of
mothers injected intramuscularly with iodized oil or saline. A total of 946
children were born, 412 to treated mothers and 534 to the saline group
mothers. Seven cretins were born to the iodine-treated mothers of whom 
6 were conceived prior to treatment (the time of treatment in relation to
conception was not known for the 7th), while 26 cretins were born to the
untreated mothers of whom 5 were conceived prior to injection. This work
clearly demonstrates that iodine deficiency is the prime cause of endemic
cretinism and that it can be prevented by improving the iodine status of
mothers before or early in pregnancy. With respect to studies in non-cretinous
Micronutrients and Mental Development 
341

1 0 1 2 3
Reference
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Bleichrodt et al. [72], 1989
Bleichrodt et al. [72], 1989
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Bleichrodt et al. [72], 1989
Collins et al. [86], 1988
Querido [87], 1978
Collins et al. [86], 1988
Muzzo et al. [88], 1986
Collins et al. [86], 1988
Huda et al. [89], 1999
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Before intervention After interventiond, SD
Age, years Country
6–15 Iran
13–20 Indonesia
2.5–6 Spain
6–12 Spain
6–12 Indonesia
0–2.5 Spain
7–14 China
5–20 New Guinea
25–45 China
6–12 Chile
0–7 China
6–8 Bangladesh
Fig. 4. Correlation of iodine deficiency with overall cognitive performance
(observational study).
NNW052327.qxd  23/06/03  1:46 PM  Page 341
Re
vi
se
s
populations, the results observed in the meta-analyses we have carried out
seemed to be consistent: the observational studies give a weighted population
effect size of 0.67 (fig. 4), which corresponds to an IQ score difference of circa 
10 points while for the intervention studies, an effect size was found of 0.56
(fig. 5), corresponding to an IQ score difference of 8 points.
Thus the observational studies indicate that iodine deficiency is associated
with impaired cognitive development, whilst the results from the intervention
studies suggest that the effects can be reversed. It would also be expected
that we could obtain some insight into when iodine deficiency impairs mental
and psychomotor development. However, in most of the studies, mothers
were supplemented with iodine prior to conception of the children studied.
Fierro-Benitz et al. [63] and Pharoah et al. [94] showed that correction of
iodine deficiency after the 5th month of pregnancy did not have any beneficial
effects on psychomotor development although Thilly [95] did. Thilly et al. [96]
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7–14 China
Lin Fa-Fu et al.
 [60], 1991
6–10 EcuadorDodge et al. [61], 1969
0–2 PeruPretell et al. [62], 1972
3.5–5.5 Ecuador
Fierro-Benitez et al. 
[63], 1972
3–5 PeruPretell et al. [62], 1972
0–2 ChinaCao et al. [64], 1994
10–12 New Guinea
Pharoah et al. 
[65, 66], 1984, 1991
7–11 BeninVan den Briel [67], 2001
5.5–12 BoliviaBautista et al. [68], 1982
12–15 Ecuador
Fierro-Benitez et al. 
[69–71], 1986, 1988
8–12 Ecuador
Fierro-Benitez et al.
 [63], 1972
6–12 Spain
Bleichrodt et al.
 [72], 1989
3–6 EcuadorTrowbridge [73], 1972
8–13 Ecuador
Fierro-Benitez et al.
 [69–71], 1986, 1988
Pooled
Fig. 5. Correlation of iodine therapy with overall cognitive performance (intervention
study).
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attributed this inconsistency to other factors, particularly goitrogens in the
diet. Thus, on the basis of these studies it is difficult to pinpoint at what stage
of pregnancy iodine deficiency affects brain development. Both in humans
and animals, transplacental transfer of maternal T4 to the fetus is crucial for
the development of the central nervous system. As mentioned earlier, the
fetus cannot make T4 in the first half of pregnancy when neuron proliferation
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Fig. 6. Correlation of iron deficiency on overall cognitive performance (observational
study).
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and migration are taking place in the brain. A recent study has correlated
maternal T4 concentrations during 12 weeks of pregnancy with impaired
infant psychomotor performance at 10 months [97]. This indicates that a state
of iodine sufficiency in the first half of pregnancy is critical for the infant,
although it cannot be excluded that the fetus and newborn are also at risk
during later stages of pregnancy and during lactation.
Some additional insights do come from animal studies. Injecting iodized oil
into iodine-deficient sheep at 100 days of their 140-day pregnancy does
restore brain growth to normal but the density of synapses in the cerebral
cortex is still less than in control fetal brains [98]. This suggests that iodine
deficiency in the first half of pregnancy is irreversible. A number of
intervention studies have been carried out in children ranging in age from 5
to 12 years. Two studies in Bolivia [68] and Bangladesh [99] did not show any
effect, while two in Malawi [59] and Benin [100] did. It may well be that the
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Fig. 7. Correlation of iron therapy on overall cognitive performance (intervention
study).
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iodine deficiency was less severe in the populations in which no effect was
found compared with those in which it was. In the study of Huda et al. [99]
the subjects were euthyroid. If the effects of iodine deficiency correction on
mental performance can be seen in children, this would suggest that not only
is the development of the fetal nervous system involved, but also through
postnatal effects of thyroid hormones. Iodine deficiency probably also affects
mental performance through an effect on hearing. In Benin, hearing
thresholds were shown to be associated with iodine status as measured by
serum thyroglobulin concentrations, while hearing thresholds were negatively
associated with performance on mental tests [101]. Studies from China have
also shown that excessive intake of iodine can lead to impaired cognitive
development [102].
From the description above of the studies on the relationship between
iodine status and mental and psychomotor development, it can be seen that
there are many unanswered questions. Although we have the methodology to
address quite a few of them, it is unlikely that many additional studies will be
carried out on the subject because of the widespread introduction of iodized
salt. Of course, the success of this public health measure should be applauded.
Iron
The meta-analysis of the observational studies on the correlations of iron
deficiency on cognitive development indicated an effect size of 0.50 (fig. 6)
corresponding to a difference in IQ score of circa 8 points. It is really
interesting to note that the effect size for the intervention study is quite high
at 0.89 (fig. 7), corresponding to an improvement in IQ of circa 13 points. It
is quite probable that this ‘over-correction’ can be explained, at least in part
by the fact that when the children were measured after the intervention, they
could remember results from the initial measurement, because the period
between the first and second measurement was very short.
Randomized Controlled Trials
We found 3 randomized controlled trials that assessed the effects of iron
sufficiency in infants at or b fore the age of 6 months. In a trial among infants
with birth weight 2,500 g, Friel et al. [103] found no difference between
infants fed formula fortified with high-dose iron compared with low-dose iron
(21 versus 13.4 mg/l) in Griffith development scores or hematological
indicators of iron status. However, the hemoglobin concentrations and serum
ferritin concentrations reported suggest that, even in the low-dose group, few
children became iron-deficient during the follow-up period. This could well
explain the low efficacy observed.
A second trial was conducted among apparently healthy, bottle-fed infants
aged 2 months from very low-income Canadian families born at or near term
(35 weeks of gestation) and with normal birth weight (2,500 g). These
infants were identified through antenatal clinics [104]. Iron fortification of
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formula (12.8 versus 1.1 mg/l) resulted in marginal improvements in hemoglobin
concentration between 6 and 15 months of age, and marginal or mild
improvements in Bayley scores for mental and motor development (maximum 6
points in psychomotor development score at 12 months of age). No or little
improvement was noticed at 6 months of age. Compliance to treatment was not
ascertained, and the considerable loss of children that occurred in the course of
the study should raise concern about possible bias. Unfortunately, no data could
be collected on maternal or infant iron status at the start of the study, so that it
is difficult to extrapolate these results to other conditions.
Thirdly, in a randomized controlled trial from Niger, it was reported that
infants whose mother had received iron had better iron status (see discussion
above) and marginally but statistically significantly higher Apgar scores 
(9.6 versus 9.2) than their peers whose mothers received placebo [47]. Apgar
scores are widely used as a screening test administered at delivery to newborns,
and are a composite of grades given for skin color, muscle tone, breathing
attempts, heart beat, and response to stimulus such as a touch or a pin prick.
The scale has some use but also limitations in predicting subsequent neurologic
and development impairment [105, 106]. Although the authors [47] claimed a
statistically significant effect on Apgar score, their use of the t test in the analysis
suggests that they inappropriately assumed that this variable is continuous and
normally distributed. Additionally, the scores reported in the placebo group were
close to 10, the maximum obtainable value. Thus the margin remaining for
improvement may have been inadequate to measure the magnitude of
improvements that may in fact have occurred (‘ceiling effect’) [107].
Several recent reports also reviewed the evidence from studies in older
children [51, 106]. A meta-analysis of randomized placebo-controlled trials in
children aged 3 years [53] showed no or little effect on mental or psychomotor
development within 30 days of iron therapy. Findings from longer-term treat-
ment were inconclusive, with only one study reporting extremely large effects
[75]. The number of studies that could be included in this review is small, 
so little can be said about variability in effects found between studies. 
The selective systematic review of therapeutic and preventive trials by
Grantham-McGregor and Ani [108] reached similar conclusions.
Following these reviews, the findings have been published from a placebo-
controlled trial among children aged 6–59 months in an area highly endemic
for malaria [51]. Subgroup analysis of the results showed that iron
supplementation during 12 months improved motor and language performance
in children with moderate anemia (hemoglobin concentrations 90 g/l).
Conclusions
There is compelling evidence that very low levels of maternal iodine intake
during pregnancy induce cretinism, and that cretinism in children can be
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prevented by supplementation of mothers. There are some indications that
maternal iodine deficiency may also impair cognitive performance in their
offspring, and evidence that such effects during infancy impairs cognitive
functioning remains inconclusive.
Adverse effects on mental and motor development of iron deficiency are
plausible and could be irreversible. If so, such effects would remain manifest
later in life, iron therapy would have no or little effect, and only preventive
interventions might be efficacious. On the other hand, such effects may be
transient and reversible by iron therapy. It is plausible that iron deficiency
causes impaired cognitive performance in preterm and/or low birth weight
infants but the evidence so far is inconclusive. Evidence of a high risk of
exposure to iron deficiency in late pregnancy and between 2 and 6 months in
infants with normal birth weights is circumstantial and has been little
considered. Given also the size of this group of children, the possibility that
such exposure may induce impaired cognitive and psychomotor performance
should raise concerns. In view of the above, there is a need for one or several
large preventive randomized placebo-controlled trials of children born at term
and with normal birth weight. These trials need to be of sufficient size and
duration to give conclusive evidence. Placebo-controlled trials in pregnant
women are probably unethical in view of government guidelines to provide
iron supplements during antenatal care.
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Discussion
Dr. Delange: Thank you for this very nice paper, which I am sure will result in a lot
of discussion. I would like to say that I insisted very much that your topic should be
on the program of this session, because I was really concerned about the methodology
of evaluating mild impairment of psychomotor and mental development in infants.
Deficiencies of micronutrients such as iron, iodine, zinc or protein usually occur in
mild forms. One of your colleagues, Dr Bleichrodt, has produced wonderful work
indicating that severe iodine deficiency results in an IQ loss of 13.5%. This is a
miraculous figure which is quoted widely. Now what about the consequences of mild
deficiencies? As a pediatrician, I am confused when reviewing the literature on the use
of tests such as the Bayley, Denver and Griffith tests. There are many tests, often
adapted for local use. So I would like to see somewhere in the proceedings of this
conference a discussion of the tests that we should be using when working in the field
in difficult conditions. I would like to indicate one major reason why I am personnally
extremely concerned by this point. As you know the big donors, when providing
money for programs, want to see success. Everybody putting money into iodization
programs wants to get a success story. And it certainly is a success story, some even
use the word ‘miracle’. Miracles are not very compatible with science I am sorry to say.
You might have seen the miraculous figure of 85 million newborns saved from brain
damage each year due to iodized salt. Isn’t that marvelous? The point is that this
miraculous figure comes from an equation which says that the number of newborns
saved from brain damage and mental retardation is the birth rate in the iodine-
deficient countries multiplied by the fraction of the population which has access to
iodized salt. That’s it. Now there are many uncertainties in this equation. You usually
don’t know the birth rate in most developing countries. Regarding the figure of access
to iodized salt, this is generally not known because it is rarely measured at the
household level. This figure is also magic, it comes from the quantity of iodized salt
produced or imported into a country divided by the total population, as simple as that.
It does not take into account what I have seen in so many countries, for example in
Cameroon, that tons of iodized salt are produced or are imported but stored in a
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warehouse somewhere, degrading progressively, losing its iodine content and never
reaching the target population. So this figure is totally unacceptable. I am absolutely
excited about what you said about iron and I am sure that iron will be discussed
extensively, but I really would like to see in the proceedings a proposal for an optimal,
simplified and universal method for evaluating mild impairment of neuro-intellectual
development. I ask this question because I am unable to provide such information. 
I am not sure that anybody would be able to, but I think that if somebody would be,
this would be your colleague, Dr. Bleichrodt.
Dr. Beard: I would like to respond to the previous comment as well as ask several
questions. Dr. Delange has asked us to generate a fairly simple feel-friendly protocol
for evaluating neuronal and emotional functioning in infants, and then be able to use
that as a predictor of functioning in later life. I think that that is an impossible task,
and I say that because I am in fact involved in a very large project with Dr. Lozoff and
others to reevaluate the developmental indexes that are the constructs of the Bayley
and the Griffith scales. Now everybody who uses these will recognize that they are
broad stroke evaluation tools; they lack specificity and sensitivity to particular neural
developmental processes. So in light of that, the new generation of studies use very
specific tests, from visual tracking tests to defined motor scales, to evoked potential
studies. These are technically fairly demanding sets of tests aimed at identifying
specific neural developmental processes that are potentially affected adversely by
deficiencies in nutrients such as iodine, iron, protein or zinc. In our particular case it
is applied to iron deficiency. So I don’t see that it is possible to boil that down to a feel-
friendly task. There are 40 different tests which we are presently performing in a study
of infants in the Detroit metropolitan area, and it is fairly complicated. The data are
going to be incredibly exciting and revealing but it is certainly not going to be feel-
friendly. Concerning your second comment about what does it all mean, I think that
there are two issues. There is a scientific question, which is what neural processes are
involved. When people quote your figures of the number of IQ points lost in iodine
deficiency, I think that this is an issue of advocacy in which you are trying to convince
donor agencies that there is a potential effect. The number may not have a scientific
basis, and I perfectly agree with you. It is the same with respect to iron when we argue
about irreversible effects in broad strokes based primarily on the Bayley scales, things
that Dr. Verhoef was talking about. What does that mean in terms of adult functioning?
It does not mean anything, or else that iron-deficient children are simply delayed in
development. That argument was fine up until about 2 years ago at which time the
very long-term longitudinal data from Dr. Lozoff’s Costa Rican studies [1] started to
come out and then the Chilean studies [2, 3]. I think that Dr. Verhoef didn’t have a
chance to deal with those findings because they weren’t really within the construct of
his talk. Using auditory evoked potentials, the studies from Chile were able for the first
time to identify a biologic process, in this case nerve conduction velocity, which 
is functioning abnormally in iron-deficient infants, and despite iron therapy. Now 
Drs. Walter and Lozoff and the other investigators have looked at these Chilean
children 5 years later. They are no longer infants, but preschool and school-age
children, and their auditory evoked potentials are still significantly slower [4]. So there
is a biological construct which says this is irreversible in children who are iron-
deficient at 6 months of age, so that there is now biological evidence. Now the second
part is what are the developmental abnormalities with the Bayley scales, the things
that Dr. Verhoef was talking about, what does that mean in later life? In Costa Rica,
children who had been studied in infancy were followed up more than 10 years later.
Dr Lozoff and colleagues [1] were able to recapture 87% of her original cohort of 191
infants, so it is a pretty miraculous longitudinal study. And when you look at that these
children who are now late adolescents and in some cases parents themselves, they
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have lower IQ, they have had more problems in school, there is more depression, there
is more anxiety, there is a whole series of adult-functioning abnormalities in these
individuals who were iron deficient in early life. So I personally am much more
confident than with the Bayley scales, that it is not so much that there is a
developmental delay but there is a little window into a process. It lacks specificity in
sensitivity but it is telling us that in all likelihood in later life individuals will not
function as well as if they would have been iron-sufficient in early life. I hope that what
we will be able to tell you in 5 years which specific processes in terms of neural
development are affected.
Dr. Sazawal: I want to make two comments. I think I agree with Dr. Beard in terms
of the Bayley scales being broad measures. But one thing that we need to keep in mind
is that the interpretation of the results of such tests in the first 2 years of life is not very
easy. So if you measure effects on test scores in the first year of life or the first 2 years
of life, how does that relate to what is actually picked up? The question is not whether
an effect that has been measured means something, because it definitively does.
However, these measurements are so insensitive at that age that the chance that you will
pick up something is very minimal. So many studies that did not find a difference may
have failed because there are no differences. On the other hand, it may simply be that
these studies did not have the potential to detect effects in the age range studied. The
second comment I have concerns the chance that you can find an effect of
supplementation within 60 days. To me, this is not plausible in view of the biology of iron
deficiency. It would require that iron supplementation corrects the deficiency as well as
the developmental process, and this is not plausible within 60 days.
Dr. Verhoef: There are obviously problems in extrapolating results from Bayley scales
measurements to impaired functioning later in life. The scores obtained with these scales
are known to have a fairly low predictive value for what happens later in life. I think that
we are mostly concerned about long-term irreversible effects. The only conclusive
evidence about this will come from a long-term well-randomized trial that measures
effects later in life. The instruments currently available can measure cognitive
development at later ages but not in early childhood. Thus if we use these instruments
at later ages, then we can be much more confident that it measures what we want to
measure. So if we are concerned for example that iron deficiency would affect IQ later
in life, then let us have a randomised controlled trial that will evaluate effects after 10
or 20 years of supplementation. I think that this would be the only type of study that
would settle this issue once and for all.
Dr. Sazawal: We did a randomized controlled trial in which, as part of a factorial
design, we gave iron or placebo to low birth weight children in the first 9 months of
life, and we are following that cohort during school age. What we have found but have
not yet published, is that, although the supplementation stopped at 9 months of age,
there were measurable group differences in Bayley scores at 15 months of age.
Dr. Verhoef: But the question remains. What does it mean?
Dr. Sazawal: Exactly, the only thing that I wanted to bring up for discussion, which
is different from Dr. Lozoff and colleagues. This is a unique population in which iron
deficiency develops in early childhood and then regular diets keep them replete for
the rest of their lives, so it is really easy to see the effects of an isolated iron deficiency
in the early years of life. But in most places especially in India and most of South Asia,
the story is the same. You can give a child therapeutic iron, bring him to a normal iron
store at the age of one year, and the next year it is down again. So you have these
processes where you have a deficiency in early infancy, a deficiency in the second year
of life and then concurrent deficiency in the later parts of the life. The challenge that
we are facing is that when you do these long-term randomized control trials, you have
to deal with this recurrence of iron deficiency.
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Dr. Verhoef: Obviously the outcome has to be ascertained after many years. In
addition, if you do a preventive trial, you should continue the intervention long enough
to cover the period of risk. Thus the intervention period should cover pregnancy and
perhaps the first year of life or so, and then the outcome should be evaluated many
years afterwards. 
Dr. Moukarzel: You showed us a recommendation for iron supplementation in
infants. Are you trying to tell us to change this recommendation and, if you had to
make a recommendation now, would you recommend iron therapy or supplementation
between 2 and 6 months in breast-fed infants?
Dr. Verhoef: I think it is too early for that. I think the evidence is still very
circumstantial and the only way to confirm that the anemia observed in this age range
is indeed due to iron deficiency is by conducting randomized control trials. There are
many confounders that must be excluded, for example vitamin A deficiency and
hereditary conditions such as thalassemia. So I think that the only way to go forward
is to conduct such randomized trials to see what can be achieved and then make
recommendations on the basis of such studies.
Dr. Beard: I would not do a placebo-controlled intervention trial in infancy
anymore. I am convinced by the data that exist now, the Indonesian study by
Idjradinata and Pollitt [5] and perhaps Dr. Sazawal’ s study, when it is published, are
the only studies to use a placebo anemic group in the design. All the other 14 clinical
intervention trials [REFS?] that have been published have not utilized placebos, and it
is intriguing that the Indonesian study is in fact the one study showing a reversibility
of effects of iron therapy. But I am convinced by those other 13 studies that there are
irreversible effects of iron deficiency in early life, so I am not going to take on 
the personal responsibility of saying I am going to include a placebo group. That may
be bad science but that is a personal decision that investigators make, I am not 
going to run a trial like that. So that leaves you with the preventative kind of trial and
I think you are raising a really good point, which is a preconception iron intervention
trial or multiple micronutrient trial in which you actually get at the notion of
micronutrient status in the first 8–10 weeks of pregnancy is the way to actually test
your hypothesis.
Dr. Verhoef: I fully agree with that. Ideally speaking that would be the case. 
Iron supplementation during pregnancy is a major policy in most countries and
therefore you cannot use placebo. On the other hand, we know that the compliance 
to iron supplementation during pregnancy is very low. This is a bad thing, of course,
but on the other hand you might use it to your advantage. Thus a trial might be
conducted whereby a comparison is made between children whose mothers were
allocated to either supervised or unsupervised iron supplementation. I am not as
convinced as you are whether it would be unethical to do iron placebo-controlled trials
in infancy and later in life., Many questions remain about the possible effects of iron
supplementation on infectious diseases. The study by Menendez et al. [6] has shown
that iron supplementation is probably safe in infants less than 6 months of age in
Tanzania or in areas of high endemic malaria. The question remains what iron
supplementation would do in older children and in children in the areas of lower
malaria endemicity. The reason why I bring this up is that the children studied by 
Dr. Menendez and colleagues [6] probably were at fairly low risk of malaria because
they supplemented iron in the first half year of life in a highly endemic malaria 
area. These children are probably protected by maternal antibodies and giving iron
would not be expected to have so much effect anyway. The question is still 
open whether the benefits of iron supplementation later in life in malaria
areasoutweigh the risk of adverse effects. For this reason, I still think that there is a
need for placebo-controlled trials to look at mortality, and the question whether iron
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supplementation prevents impairment in cognitive development could also be studied
in such a trial.
Dr. Sazawal: In the Tanzanian trial that we are doing to assess the effect of zinc
supplementation on mortality, there is also a factorial whereby about 30,000 children
are randomized to receive supplements with either iron or its placebo from the age of
1 month onwards. So probably within the next 1.5 years we should have data on 
the effects of iron supplementation on mortality. My personal view is that there is a 
lot of data on iron supplementation in malaria areas but that there is a big gap in our
knowledge of the effect of iron supplementation on other infectious diseases in
developing countries, particularly where the prevalence of such infections is very high.
There are very few data from South Asia with regard to the effects of iron
supplementation in settings where 40–50% of babies afer of low birth weightThese
infants are basically malnourished during the first year of life, they have about 8–10
episodes of diarrhea and 1.5–2 episodes of pneumonia, and have recurrent infestation
in the first 2 years of life. Now in that setting, what happens when you give a long-term
high-dose iron therapy is still an open question.
Dr. Verhoef: It certainly is. Let me add that we have just published a study looking
at the effects of iron supplementation in slightly older children than were studied
previously in the Tanzania trial by Menendez and colleagues [6]. The best estimate is
that it probably leads to a perhaps 20% increase in malaria if you use twice weekly iron
supplementation. But the confidence interval, as indicated by its upper limit, is still
compatible with the 3-fold increase and that remains a big worry. I do think there is a
need for a large trial that really addresses this question, not only for malaria but also
for other infectious diseases.
Dr. Allen: I would like to make a couple of comments that are issues that have
arisen from the studies by Dewey, Domeloff and colleagues [7, 8]. Even well-nourished
iron-replete babies in Sweden during the first 4 months of age responded by increasing
their hemoglobin concentration when they were supplemented with iron. Hemoglobin
is not a good indicator of iron status during the first 2 months of life. Secondly, the
cutoffs that are being used right now seem to be wrong for hemoglobin and probably
for ferritin, and new cutoffs have been suggested for most iron status measures in
infancy [7]. Thirdly, iron supplementation from 4 to 9 months produces no additional
benefits at 9 months compared to iron supplementation between 6 and 9 months.
Another general question is what happens to these children when we stop these
supplementation trials and we let them to go back to where they were before? Nobody
is going to supplement children forever, and this always bothers me.
Dr. Verhoef: It is true that there are a number of questions on how to determine
iron status in the very young. I am a bit puzzled by your comment that if you give iron
supplementation you get an increase in hemoglobin concentration and therefore it is
not a good indicator. I fail to see the rationale for that.
Dr. Allen: This was in Swedish babies who are known to be iron-replete and getting
iron-loaded formulas, and still when they were given additional iron supplements, the
hemoglobin went up even more.
Dr. Verhoef: I don’t understand why you infer from such data that hemoglobin is
not a good indicator of anemia. To me, that doesn’t necessarily seem to be indicated
by the results that you quote. It might be that increasing hemoglobin concentrations
when they are close to their maximum may be beneficial, but it appears to me that this
is not indicated by the evidence that you refer to. I missed the second part of your
question, sorry.
Dr. Allen: It was a general question on all of these studies about the ethics of
supplementing and then stopping. I don’t have an answer right here but we should
think about it.
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Dr. Verhoef: On the other hand I question whether it is yet ethical to use iron
supplementation in malaria areas. Although evidence is accumulating that it is safe,
larger trials are required to settle this issue with certainty.
Dr. Zlotkin: Just in response to Dr. Allen’s question on sustainability. We have just
completed a relatively short-term 2-month trial of supplementing anemic infants in
Ghana. The infants who responded positively to the supplementation were
randomized into 4 groups, 1 was a placebo group and another group received iron, and
followed these infants for the next 18 months. And what we found was that, after 2
months of adequate treatment, the majority of the infants remain nonanemic for the
next 18 months. So it is possible that a relatively short period of adequate treatment
will last for a relatively long period of time.
Dr. Verhoef: This also seems to be indicated by the results of the study by
Menendez and colleagues [6], which showed that if you give iron between 8 and 24
weeks of age, the effects on reducing the incidence of severe anemia seem to be
sustained over the entire first year of life. I presume that this indicates that iron stores
are built up to some degree.
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